Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 498Rectal Neoplasms 268Colonic Neoplasms 219Pancreatic Neoplasms 190Stomach Neoplasms 183Esophageal Neoplasms 135Neoplasm Metastasis 98Adenocarcinoma Of Esophagus 67Esophageal Squamous Cell Carcinoma 62Carcinoma, Hepatocellular 56Neoplasms 44Cholangiocarcinoma 33Biliary Tract Neoplasms 27Adenocarcinoma 27Anus Neoplasms 26Gastrointestinal Neoplasms 25Gallbladder Neoplasms 22Liver Neoplasms 21Carcinoma, Non-Small-Cell Lung 20Bile Duct Neoplasms 19Parkinson Disease 4, Autosomal Dominant Lewy Body 16Ovarian Neoplasms 11Digestive System Neoplasms 10Colorectal Cancer Metastatic 10Carcinoma, Squamous Cell 10Peritoneal Neoplasms 9Breast Neoplasms 9Anal Canal Carcinoma 9Lung Neoplasms 8Head and Neck Neoplasms 8

Interventions

xaliproden 2Polyamines 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paresthesia × Fluorouracil × Gastrointestinal × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡